Effectiveness of crizotinib in a patient with mesenchymal-epithelial transition overexpression/fluorescence in situ hybridization-negative/next-generation sequencing-negative advanced lung adenocarcinoma: a case report

Crizotinib, an oral ATP-competitive tyrosine kinase inhibitor (TKI), has shown significant activity against advanced non-small cell lung cancer (NSCLC) tumors harboring mesenchymal-epithelial transition (MET) amplification or exon 14 mutation. Methods to detect MET alteration includes immunohistoche...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Peng, Liu, Li, Liu, Yutao, Zhang, Tao, Guo, Lei, Li, Weihua, Ying, Jianming, Yang, Lin, Gao, Shugeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798553/
https://www.ncbi.nlm.nih.gov/pubmed/35116804
http://dx.doi.org/10.21037/tcr.2019.03.14
_version_ 1784641835731255296
author Song, Peng
Liu, Li
Liu, Yutao
Zhang, Tao
Guo, Lei
Li, Weihua
Ying, Jianming
Yang, Lin
Gao, Shugeng
author_facet Song, Peng
Liu, Li
Liu, Yutao
Zhang, Tao
Guo, Lei
Li, Weihua
Ying, Jianming
Yang, Lin
Gao, Shugeng
author_sort Song, Peng
collection PubMed
description Crizotinib, an oral ATP-competitive tyrosine kinase inhibitor (TKI), has shown significant activity against advanced non-small cell lung cancer (NSCLC) tumors harboring mesenchymal-epithelial transition (MET) amplification or exon 14 mutation. Methods to detect MET alteration includes immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), next-generation sequencing (NGS) and reverse transcription polymerase chain reaction (RT-PCR). Despite multiple methods for detecting MET alteration, the response to crizotinib in advanced NSCLC patients according to the results of MET IHC staining is still unknown. This case showed effectiveness of crizotinib in a pretreated patient with advanced lung adenocarcinoma detected as MET overexpression/FISH-negative/NGS-negative. MET overexpression might be a biomarker for predicting efficacy of crizotinib.
format Online
Article
Text
id pubmed-8798553
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87985532022-02-02 Effectiveness of crizotinib in a patient with mesenchymal-epithelial transition overexpression/fluorescence in situ hybridization-negative/next-generation sequencing-negative advanced lung adenocarcinoma: a case report Song, Peng Liu, Li Liu, Yutao Zhang, Tao Guo, Lei Li, Weihua Ying, Jianming Yang, Lin Gao, Shugeng Transl Cancer Res Case Report Crizotinib, an oral ATP-competitive tyrosine kinase inhibitor (TKI), has shown significant activity against advanced non-small cell lung cancer (NSCLC) tumors harboring mesenchymal-epithelial transition (MET) amplification or exon 14 mutation. Methods to detect MET alteration includes immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), next-generation sequencing (NGS) and reverse transcription polymerase chain reaction (RT-PCR). Despite multiple methods for detecting MET alteration, the response to crizotinib in advanced NSCLC patients according to the results of MET IHC staining is still unknown. This case showed effectiveness of crizotinib in a pretreated patient with advanced lung adenocarcinoma detected as MET overexpression/FISH-negative/NGS-negative. MET overexpression might be a biomarker for predicting efficacy of crizotinib. AME Publishing Company 2019-04 /pmc/articles/PMC8798553/ /pubmed/35116804 http://dx.doi.org/10.21037/tcr.2019.03.14 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Case Report
Song, Peng
Liu, Li
Liu, Yutao
Zhang, Tao
Guo, Lei
Li, Weihua
Ying, Jianming
Yang, Lin
Gao, Shugeng
Effectiveness of crizotinib in a patient with mesenchymal-epithelial transition overexpression/fluorescence in situ hybridization-negative/next-generation sequencing-negative advanced lung adenocarcinoma: a case report
title Effectiveness of crizotinib in a patient with mesenchymal-epithelial transition overexpression/fluorescence in situ hybridization-negative/next-generation sequencing-negative advanced lung adenocarcinoma: a case report
title_full Effectiveness of crizotinib in a patient with mesenchymal-epithelial transition overexpression/fluorescence in situ hybridization-negative/next-generation sequencing-negative advanced lung adenocarcinoma: a case report
title_fullStr Effectiveness of crizotinib in a patient with mesenchymal-epithelial transition overexpression/fluorescence in situ hybridization-negative/next-generation sequencing-negative advanced lung adenocarcinoma: a case report
title_full_unstemmed Effectiveness of crizotinib in a patient with mesenchymal-epithelial transition overexpression/fluorescence in situ hybridization-negative/next-generation sequencing-negative advanced lung adenocarcinoma: a case report
title_short Effectiveness of crizotinib in a patient with mesenchymal-epithelial transition overexpression/fluorescence in situ hybridization-negative/next-generation sequencing-negative advanced lung adenocarcinoma: a case report
title_sort effectiveness of crizotinib in a patient with mesenchymal-epithelial transition overexpression/fluorescence in situ hybridization-negative/next-generation sequencing-negative advanced lung adenocarcinoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798553/
https://www.ncbi.nlm.nih.gov/pubmed/35116804
http://dx.doi.org/10.21037/tcr.2019.03.14
work_keys_str_mv AT songpeng effectivenessofcrizotinibinapatientwithmesenchymalepithelialtransitionoverexpressionfluorescenceinsituhybridizationnegativenextgenerationsequencingnegativeadvancedlungadenocarcinomaacasereport
AT liuli effectivenessofcrizotinibinapatientwithmesenchymalepithelialtransitionoverexpressionfluorescenceinsituhybridizationnegativenextgenerationsequencingnegativeadvancedlungadenocarcinomaacasereport
AT liuyutao effectivenessofcrizotinibinapatientwithmesenchymalepithelialtransitionoverexpressionfluorescenceinsituhybridizationnegativenextgenerationsequencingnegativeadvancedlungadenocarcinomaacasereport
AT zhangtao effectivenessofcrizotinibinapatientwithmesenchymalepithelialtransitionoverexpressionfluorescenceinsituhybridizationnegativenextgenerationsequencingnegativeadvancedlungadenocarcinomaacasereport
AT guolei effectivenessofcrizotinibinapatientwithmesenchymalepithelialtransitionoverexpressionfluorescenceinsituhybridizationnegativenextgenerationsequencingnegativeadvancedlungadenocarcinomaacasereport
AT liweihua effectivenessofcrizotinibinapatientwithmesenchymalepithelialtransitionoverexpressionfluorescenceinsituhybridizationnegativenextgenerationsequencingnegativeadvancedlungadenocarcinomaacasereport
AT yingjianming effectivenessofcrizotinibinapatientwithmesenchymalepithelialtransitionoverexpressionfluorescenceinsituhybridizationnegativenextgenerationsequencingnegativeadvancedlungadenocarcinomaacasereport
AT yanglin effectivenessofcrizotinibinapatientwithmesenchymalepithelialtransitionoverexpressionfluorescenceinsituhybridizationnegativenextgenerationsequencingnegativeadvancedlungadenocarcinomaacasereport
AT gaoshugeng effectivenessofcrizotinibinapatientwithmesenchymalepithelialtransitionoverexpressionfluorescenceinsituhybridizationnegativenextgenerationsequencingnegativeadvancedlungadenocarcinomaacasereport

Ejemplares similares